Amitriptyline for fibromyalgia in adults

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 10, 2015, Pages

  Moore, R Andrew ^a   Derry, Sheena ^a   Aldington, Dominic ^b   Cole, Peter ^c   Wiffen, Philip J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ROYAL HAMPSHIRE COUNTY HOSPITAL   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; PLACEBO;

ADULT; ANALGESIA; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; FIBROMYALGIA; HUMAN; OUTCOME ASSESSMENT; PAIN INTENSITY; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 84942932528     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011824     Document Type: Review

References (79)

1. Braz AS, Morais LC, Paula AP, Diniz MF, Almeida RN. Effects of Panax ginseng extract in patients with fibromyalgia: a 12-week, randomized, double-blind, placebo-controlled trial. Revista Brasileira de Psiquiatria 2013;35(1):21-8. [DOI: 10.1016/j.rbp.2013.01.004]3174836
2. Carette S, McCain GA, Bell DA, Fam AG. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis and Rheumatism 1986;29(5):655-9. 3174838
3. Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial. Arthritis and Rheumatism 1994;37(1):32-40. 3174840
4. Carette S, Oakson G, Guimont C, Steriade M. Sleep electroencephalography and the clinical response to amitriptyline in patients with fibromyalgia. Arthritis and Rheumatism 1995;38(9):1211-7. 3174842
5. Cauma W (Principle investigator). Immune-Pineal Axis Function in Fibromyalgia. www.clinicaltrials.gov/ct2/show/NCT02041455?term=NCT02041455&rank=1 (accessed 30 Mar 15) 2014. [CTG: NCT02041455]3174844
6. de Zanette SA, Vercelino R, Laste G, Rozisky JR, Schwertner A, Machado CB, et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology 2014;15:40. [DOI: 10.1186/2050-6511-15-40]3174845
7. Ginsberg F, Mancaux A, Joos E, Vanhove P, Famey J-P. A randomized placebo-controlled trial of sustained-release amitriptyline in fibromyalgia. Journal of Musculoskeletal Pain 1996;4(3):37-47. 3174847
8. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism 1986;29(11):1371-7. 3174849
9. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism 1996;39(11):1852-9. 3174851
10. Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. British Journal of Rheumatology 1998;37(12):1279-86. 3174853
11. Fors EA, Sexton H, Götestam KG. The effect of guided imagery and amitriptyline on daily fibromyalgia pain: a prospective, randomized, controlled trial. Journal of Psychiatric Research 2002;36(3):179-87. 3174855
12. Hampf G, Bowsher D, Nurmikko T. Distigmine and amitriptyline in the treatment of chronic pain. Anesthesia Progress 1989;36(2):58-62. 3174857
13. Heymann RE, Helfenstein M, Feldman D. A double-blind, randomized, controlled study of amitriptyline, nortriptyline and placebo in patients with fibromyalgia. An analysis of outcome measures. Clinical and Experimental Rheumatology 2001;19(6):697-702. 3174859
14. Isomeri R, Mikkelsson M, Latikka P, Kammonen K. Effects of amitriptyline and cardiovascular fitness training on pain in patients with primary fibromyalgia. Journal of Musculoskeletal Pain 1993;1(3/4):253-60. 3174861
15. Jaeschke R, Adachi J, Guyatt G, Keller J, Wong B. Clinical usefulness of amitriptyline in fibromyalgia: the results of 23 N-of-1 randomized controlled trials. Journal of Rheumatology 1991;18(3):447-51. 3174863
16. Kempenaers C, Simenon G, Vander Elst M, Fransolet L, Mingard P, de Maertelaer V, et al. Effect of an antidiencephalon immune serum on pain and sleep in primary fibromyalgia. Neuropsychobiology 1994;30(2-3):66-72. 3174865
17. McQuay HJ, Carroll D, Glynn CJ. Low dose amitriptyline in the treatment of chronic pain. Anaesthesia 1992;47(8):646-52. 3174867
18. McQuay HJ, Carroll D, Glynn CJ. Dose-response for analgesic effect of amitriptyline in chronic pain. Anaesthesia 1993;48(3):281-5. 3174869
19. Özerbil O, Okudan N, Gökbel H, Levendoglu F. Comparison of the effects of two antidepressants on exercise performance of the female patients with fibromyalgia. Clinical Rheumatology 2006;25(4):495-7. 3174871
20. Pilowsky I, Hallett EC, Bassett DL, Thomas PG, Penhall RK. A controlled study of amitriptyline in the treatment of chronic pain. Pain 1982;14(2):169-79. 3174873
21. Pilowsky I, Barrow CG. A controlled study of psychotherapy and amitriptyline used individually and in combination in the treatment of chronic intractable, 'psychogenic' pain. Pain 1990;40(1):3-19. 3174875
22. Scudds RA, McCain GA, Rollman GB, Harth M. Improvements in pain responsiveness in patients with fibrositis after successful treatment with amitriptyline. Journal of Rheumatology Supplement 1989;19:98-103. 3174877
23. Zitman FG, Linssen AC, Edelbroek PM, Stijnen T. Low dose amitriptyline in chronic pain: the gain is modest. Pain 1990;42(1):35-42. 3174879
24. Zitman FG, Linssen AC, Edelbroek PM, Van Kempen GM. Does addition of low-dose flupentixol enhance the analgetic effects of low-dose amitriptyline in somatoform pain disorder?. Pain 1991;47(1):25-30. 3174881
25. Capaci K, Hepgüler S. Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. The Pain Clinic 2002;14(3):223-8. 3174883
26. Ataoglu S, Ataoglu A, Erdogan F, Sarac J. Comparison of paroxetine, amitriptyline in the treatment of fibromyalgia. Turkish Journal of Medical Science 1997;27(6):535-9. 3174885
27. Jang ZY, Li CD, Qiu L, Guo JH, He LN, Yue Y, et al. Combination of acupuncture, cupping and medicine for treatment of fibromyalgia syndrome: a multi-central randomized controlled trial. Zhongguo Zhen Jiu [Chinese Acupuncture and Moxibustion] 2010;30(4):265-9. 3174887
28. Ware MA (Principle Investigator). Nabilone versus amitriptyline in improving quality of sleep in patients with fibromyalgia. www.clinicaltrials.gov/ct2/show/NCT00381199?term=NCT00381199&rank=1 (accessed 30 March 2015) 2007. [CTG: NCT00381199]3174889
29. Dechartres A, Trinquart L, Boutron I, Ravaud P. Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ 2013;346:f2304. [DOI: 10.1136/bmj.f2304]
30. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105-21. [DOI: 10.1016/j.jpain.2007.09.005]
31. Häuser W, Petzke F, Üçeyler N, Sommer C. Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. Rheumatology (Oxford) 2011;50(3):532-43. [DOI: 10.1093/rheumatology/keq354]
32. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
33. Higgins JPT, Green S (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Altman DG, Sterne JAC editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
34. Jadad AR, Carroll D, Moore RA, McQuay H. Developing a database of published reports of randomised clinical trials in pain research. Pain 1996;66(2-3):239-46.
35. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1-12. [DOI: doi.org/10.1016/0197-2456(95)00134-4]
36. Kalso E, Aldington DJ, Moore RA. Drugs for neuropathic pain. BMJ 2013;347:f7339. [DOI: 10.1136/bmj.f7339]
37. Kim SC, Landon JE, Lee YC. Patterns of health care utilization related to initiation of amitriptyline, duloxetine, gabapentin or pregabalin in fibromyalgia. Arthritis Research and Therapy 2015;17(1):18. [DOI: 10.1186/s13075-015-0530-8]
38. Kjaergard LL, Villumsen J, Gluud C. Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Annals of Internal Medicine 2001;135(11):982-9.
39. Koroschetz J, Rehm SE, Gockel U, Brosz M, Freynhagen R, Tölle TR, et al. Fibromyalgia and neuropathic pain - differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia. BMC Neurology 2011;11:55. [DOI: 10.1186/1471-2377-11-55]
40. L'Abbé KA, Detsky AS, O'Rourke K. Meta-analysis in clinical research. Annals of Internal Medicine 1987;107:224-33.
41. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3]
42. McQuay H, Moore R. An evidence-based resource for pain relief. Oxford: Oxford University Press, 1998. [ISBN: 0-19-263048-2]
43. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]
44. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978-0-931092-69-5]
45. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI: 10.1002/14651858.CD007076]
46. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief, Cochrane Pain, Palliative and Supportive Care Systematic Review Group Editors. "Evidence" in chronic pain - establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386-9. [DOI: 10.1016/j.pain.2010.05.011]
47. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374-9. [DOI: 10.1136/ard.2009.107805]
48. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360-4. [DOI: 10.1016/j.pain.2010.02.039]
49. Moore RA, Derry S, McQuay HJ, Straube S, Aldington D, Wiffen P, et al. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain 2010;149(2):173-6. [DOI: 10.1016/j.pain.2009.08.007]
50. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982-9. [DOI: doi:10.1016/j.pain.2010.11.030]
51. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427-32. [DOI: 10.1097/EJA.0b013e328343c569]
52. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.00]
53. Moore RA, Straube S, Aldington D. Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome. Anaesthesia 2013;68(4):400-12. [DOI: 10.1111/anae.12148]
54. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690]
55. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice 2014;14(1):79-94.
56. Moore RA, Wiffen PJ, Derry S, Toelle T, Rice AS. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2014, Issue 4. [DOI: 10.1002/14651858.CD007938.pub3]
57. Moore RA, Cai N, Skljarevski V, Tölle TR. Duloxetine use in chronic painful conditions - individual patient data responder analysis. European Journal of Pain 2014;18(1):67-75. [DOI: 10.1002/j.1532-2149.2013.00341.x]
58. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2015, Issue 7. [DOI: 10.1002/14651858.CD008242.pub3]
59. Nishishinya B, Urrútia G, Walitt B, Rodriguez A, Bonfill X, Alegre C, et al. Amitriptyline in the treatment of fibromyalgia: a systematic review of its efficacy. Rheumatology (Oxford) 2008;47(12):1741-6. [DOI: 10.1093/rheumatology/ken317]
60. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515. [DOI: 10.1136/bmj.c3515]
61. Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010;341:c3515. [DOI: 10.1136/bmj.c3515]
62. Onghena P, Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo-controlled studies. Pain 1992;49:205-20.
63. PaPaS author and referee guidance. http://papas.cochrane.org/papas-documents (accessed 9 March 2015).
64. Anonymous. Prescription Cost Analysis, England 2013. Available at: hscic.gov.uk/catalogue/PUB13887/pres-cost-anal-eng-2013-rep.pdf (Accessed 9 March 2015). Health and Social Care Information Centre, 2014:100-1. [ISBN: 978-1-78386-089-0]
65. Queiroz LP. Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports 2013;17(8):356. [DOI: 10.1007/s11916-013-0356-5]
66. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
67. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, Guyatt GH. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
68. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia--responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150]
69. Straube S, Moore RA, Paine J, Derry S, Phillips CJ, Hallier E, et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BMC Musculoskeletal Disorders 2011;12:125. [DOI: 10.1186/1471-2474-12-125]
70. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29]
71. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163-96. [DOI: 10.1016/S0140-6736(12)61729-2]
72. Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice ASC, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD010567.pub2]
73. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis and Rheumatism 1990;33:160-72.
74. Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, Katz RS, Mease P, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care and Research 2010;62(5):600-10. [DOI: 10.1002/acr.20140]
75. Wolfe F, Brähler E, Hinz A, Häuser W. Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population. Arthritis Care and Research 2013;645(5):777-85. [DOI: 10.1002/acr.21931]
76. Wolfe F, Walitt BT, Häuser W. What is fibromyalgia, how is it diagnosed and what does it really mean?. Arthritis Care and Research 2014;66(7):969-71. [DOI: 10.1002/acr.22207]
77. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996;68:217-27.
78. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2]
79. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD005454.pub2]